Tomoya Takeda
Hakodate, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 80 publications
The Ethanol-Insoluble Low-Molecular-Weight Fraction LEP-4 Derived From Lentinula edodes Mycelia Extract Attenuates Oxaliplatin-Evoked Allodynia in Mice.
Journal: Advances in pharmacological and pharmaceutical sciences
Published: February 12, 2026
Draft genome sequence of a marine coccolithophore Chrysotila carterae NIES-4509.
Journal: Microbiology resource announcements
Published: June 09, 2025
Combination of 3-(Trihydroxygermyl)propanoic Acid (THGP) and Lipopolysaccharide Promotes Macrophage Differentiation to M1, and Antitumor Activity.
Journal: Anticancer research
Published: May 23, 2025
The Organogermanium Compound 3-(trihydroxygermyl)propanoic Acid Exerts Anti-Inflammatory Effects via Adenosine-NR4A2 Signaling.
Journal: International journal of molecular sciences
Published: February 19, 2025
Overexpression of miR-29a and miR-29b is involved in imatinib resistance via abrogated NF1 expression and increased ERK1/2 activation in chronic myeloid leukemia cells.
Journal: Medical oncology (Northwood, London, England)
Published: January 09, 2025
Organogermanium: Potential beneficial effects on the cardiovascular system.
Journal: Physiological reports
Published: October 14, 2024
Oxaliplatin and 5-fluorouracil promote epithelial-mesenchymal transition via activation of KRAS/ERK/NF-κB pathway in KRAS-mutated colon cancer cells.
Journal: Molecular and cellular biochemistry
Published: March 08, 2024
RANK/RANKL axis promotes migration, invasion, and metastasis of osteosarcoma via activating NF-κB pathway.
Journal: Experimental cell research
Published: January 24, 2024
Inhibitory effect of organogermanium compound 3-(trihydroxygermyl)propanoic acid on fructose-induced glycation of amino compounds.
Journal: Carbohydrate research
Published: November 28, 2023
HER3/Akt/mTOR pathway is a key therapeutic target for the reduction of triple‑negative breast cancer metastasis via the inhibition of CXCR4 expression.
Journal: International journal of molecular medicine
Published: March 13, 2023
Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukaemia cells.
Journal: Cell proliferation
Published: November 28, 2022
Last Updated: 09/26/2026